2Seventy Bio Inc

2Seventy Bio — Investor Presentation (January 2022)

30 slides from 2Seventy Bio's investor presentation, Jan 11, 2022

  1. Slide 1: Join the Patient Mission: 2022 Full Year Outlook

    Join the Patient Mission 2022 Full Year Outlook January 2022 eseventybio.

  2. Slide 2: Cautionary note regarding forward-looking statements

    Cautionary note regarding forward-looking statements plans, strategies, timeli i i sale of our i i i ign, initiation, enrollment including our net revenue for implied by any including, without limitation. y thereto, i pacity i i filing by the F imeli is plans with i i i imeli t all; cash use for ope

  3. Slide 3: It's about time

    It's about time The most committed and passionate geeks driving next gen oncology cell therapeutics ; eseventybio”

  4. Slide 4: Key "launch" ingredients and plans years in the making

    Key “launch” ingredients and plans 12 years in the making People + Culture Experience Eo Product Engine Double Down Science, translation, capabilities ABECMA® Deliver to patients and scale to demand NextGen Potential Proof-of-Concept Test, learn & iterate in the clinic Disrupt Relentless innovation

  5. Slide 5: Horizons focused on long term learning and disruption

    Horizons focused on long term learning and disruption Horizon 0: Launch Company Horizon 2: Clinical Pipeline Spin & Focus Team Double Down & Burn Launch & 3% Line & Integration \ Scale Beyond ecenenere Solid Tumors: Rapid B-NHL & AML MUC16, MAGE-A4 Innovation ‘ & Beyond Cy cle / Deep Deep Auto In-Vi

  6. Slide 6: 2022 Goals — Transformative build & deliver year

    2022 Goals — Transformative build & deliver year Deliver Amp Up ABECMA® Product Engine Anticipated $250-$300M B-NHL & AML; US revenue advance in in 2022 solid tumors Geek Goal - Make Disruption Plans Real (e.g., Data) B-NHL: B-cell non-Hodgkin lymphoma . vA 7 AML: acute myeloid leukemia eseventybio:

  7. Slide 7: Delivering on multiple horizons

    Delivering on multiple horizons Horizon X: Deep Geek Emerging and undisclosed. Disruptive next-gen... Horizon 2: Pipeline . : $1-2B late line global revenue** povour 1: Commercial backstop. Increasing mfg. capabilities alan eG Wii process improvement Source of funding. — . Earlier line studies Earli

  8. Slide 8: ABECMA expected to be $1-2B late line global market opportunity

    ABECMA® expected to be $1-2B late line global market opportunity 2021 Launch 2022 Outlook 2023 and Beyond + Approved on March 26, 2021 * Anticipated $250-300M US product net * 3L topline data and potential BLA * Significant demand to date from revenue Sulmnfestor - patients and physicians + Increasi

  9. Slide 9: 2seventy's R&D philosophy - accelerating innovation

    2seventy’s R&D philosophy - accelerating innovation Autologous CAR T cells work, + Identify fundamental problems but their full potential has not yet been realized + Look beyond the horizon + Explore new biology eo! Multiple approved autologous CAR T products establish a powerful platform on which t

  10. Slide 10: R&D engine built to rapidly design, test, learn, & iterate

    R&D engine built to rapidly design, test, learn, & iterate . N N N @ vecToroLocy S TCR CCR pee ues e Maximize payload, DESIGN LVV mRNA a at innovative des sign, ( , of am > } oy optimize component Vv «a 8 spews S. A = 3 eS ENHANCED CO-STIM REGULATED oO omelet OBTCELLS ySTCELLS 2 fe Mi >) next level,

  11. Slide 11: Innovative cell therapy candidates across broad indications

    Innovative cell therapy candidates across broad indications INDICATION [DRUG] TARGET Multiple Myeloma [ABECMA] Bat Multiple Myeloma [ABECMA] Bais AML-Pediatric [DARIC33] CD33 B-NHL. Dual B cell [bbT369] targets AML-Adult CD33 + [DARIC33 Next-Gen] Undisclosed Ovarian Cancer [b6T4015] Muct6 Solid Tumo

  12. Slide 12: bbT369: Designed with purpose. IND cleared.

    bbT369: Designed with purpose. IND cleared. bbT369 eliminates challenging tumors How to get there: I th nA +i potency- failure modes of CD19 CAR-Ts Novel combination of antigens to address antigen escape. signaling T cell activation. Gene edit to enhance potency and reduce T cell exhaustion. Executi

  13. Slide 13: CRC-403 study in B-NHL open and enrolling

    CRC-403 study in B-NHL open and enrolling CRC-403: A Phase 1/2 Study of bbT369 in Relapsed and/or Refractory B-Cell Non-Hodgkin Lymphoma (B-NHL) Assessment day -5 -2 day 0 day 0-30 day 30 STUDY DESIGN + Target enrollment: n=50 * 4 study sit . elec B-cell NHL after autologous SCT 2 2 prior lines of t

  14. Slide 14: SC-DARIC33: Engineered to kickstart CAR T cell therapy in AML

    SC-DARIC33: Engineered to kickstart CAR T cell therapy in AML How to get there: Drug regulated CAR Ts overcome the iinderlyi lacia rick of targeting myeloid cells Enhance CAR T cell persistence by reducing exhaustive effect of vy Targeting the C2 domain of CD33 designed to deliver target limiting an

  15. Slide 15: Phase I study (PLAT-08) open and enrolling

    Phase | study (PLAT-08) open and enrolling Study Design: A Study Of SC-DARIC33 In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML day -5-2 day 0 day 2 day 21 day 42 STUDY DESIGN + Single-center, academic study + Target omolment N=18 + Age $ 28 year: * Relapsed or a CD33+ AML + Prior

  16. Slide 16: 2seventy's attack on solid tumors designed to address the key barriers to success

    2seventy’s attack on solid tumors designed to address the key barriers to success Can we achieve sensitive & Can we convert suppressive multiplex targeting across the full signals to supportive ones, and range of target classes? re-engage innate immunity? FLIP GENE SIGNAL 3 ONCOLYTIC RECEPTORS EDITI

  17. Slide 17: MAGEA4-CTBR12: Solid tumors

    MAGEA4-CTBR12: Solid tumors What if T cells can deliver heme cancer- like outcomes for patients? Can we substantially enhance the potency of a TCR T cell using a TME Signal conversion technology? Patients without Disease Progression or Death (%) Problem Some roundly immunosuppressive pathways are di

  18. Slide 18: DREAM

    DREAM Strive to create a product that: . tT ts MUC16- iti lid t largets M no, of di (expressed in Unleashes the potential of T cells in y synergizing with microenvironment (TME), target activity How to get there: Abold product concept combining an engineered T cell ane a potent pharmacologic agen\ *

  19. Slide 19: Ovarian Cancer [DEVISE]: Pre-clinical data demonstrate deep responses

    Ovarian Cancer [DEVISE]: Pre-clinical data demonstrate deep responses MUC16 CAR exhibits MUC16 ectodomain (“nub”) specificity - does not bind shed CA125 Solution CAR vs “nub” [surface retained] CAR vs CA125 [shed] IFNy (pglmL) 10 100 1000-10000 ‘Muc16 nub concentration (ngimL) IFNy (pg/mL) o 10 1000

  20. Slide 20: A MUC16 CAR T cell therapy must overcome several challenges

    A MUC16 CAR T cell therapy must overcome several challenges to be successful in ovarian cancer Physical barriers Suppressive cells & cytokines Impaired antigen presentation Oxygen deprivation Inhibitory ligands Nutrient deprivation Toxic metabolites = te F Cancer cells Cancer: extacelar Tum ‘amor: a

  21. Slide 21: Our MUC16 program realizes the scientific power of collaboration with Regeneron

    Our MUC16 program realizes the scientific power of collaboration with Regeneron MUC16 Know-how Mouse models, huAbs & pre-clinical data ‘YY VELOCIMMUNE* Fully human antibodies MEDICINE | RESEARCH ARTICLE Tumor targeted co-stimulation Multiple CD28 bispecifics in pre clinical and clinical developmer R

  22. Slide 22: Innovative cell therapy candidates across broad indications

    Innovative cell therapy candidates across broad indications IND-ENABLING CLIN. STUDIES DISCOVERY STAGE R&D BMS Partns BMS tudies rtnership; E TsV SCRI Collaboration CLINICAL STUDIES APPROVED PRODUCTS Label Expansion REGN Collaboration 2023 IND Submission INDICATION [DRUG] TARGET TECHNOLOGY Multiple

  23. Slide 23: Horizons focused on long term learning and disruption

    Horizons focused on long term learning and disruption 4 . Spin & Focus Team Horizon 0: Launch Company —_ SSRiaare eB Launch & 3° Line & Integration \ Scale Beyond a quid Tumors: Solid Tumors: Rapid \ Horizon 2: Clinical Pipeline TERRA, MUC16, MAGE-A4 Innovation ; H & Beyond Cycle ( Deep Deep Auto In

  24. Slide 24: What are the biological barriers to achieving deep and durable responses?

    What are the biological barriers to achieving deep and durable responses? Low or reduced target abundance Target loss & heterogeneous expression Poor T cell engraftment and persistence Immunosuppressive microenvironment Cancer immune cycle breakdown TCRs >> CARs ee -| Multi-log sensitivity delta in

  25. Slide 25: 2seventy's novel receptor architecture: a new platform for tumor targeting

    2seventy’s novel receptor architecture: a new platform for tumor targeting We h hauled antig ptor design and significantly advanced our targeting capabiliti An orthogonal approach to Enables simultaneous targeting Compact, readily engineered, improved T cell signaling and of BOTH cell surface AND an

  26. Slide 26: F8-GE: Novo Nordisk Partnered Program to Leverage Gene Editing

    F8-GE: Novo Nordisk Partnered Program to Leverage Gene Editing Capabilities Directly in vivo for Durable Hemophilia A Gene Therapy Hepatocyte Op @ Payload release Gk N ZO wSI™ LNP Adeno-associated virus (AAV) (megaTAL mRNA) Therapeutic transgene “ 0; QO 0 a. pis. : i A megaTAL / f AAV 4 ee) Ses AFR

  27. Slide 27: 2seventy's manufacturing network: Poised to deliver

    2seventy’s manufacturing network: Poised to deliver WSIS TRV Sure bestin-class academic paresis exploratory programs Enable pipeline speed & . i we e decision making t flexibility & 2seventy resources proof-of-concept . ir i network Establish an in-house clinical drug product INNOVATION manufacturin

  28. Slide 28: Our seasoned team is ready

    Our seasoned team is ready ecto! Nick Leschly Chip Bai Nicola Heffron Philip Gregory, D. Phil. Sarah Glickman Ramy Ibrahim, M.D. Michael Jensen, M.D.* chief kairos officer* Chief eee Officer Chief Operating Officer Chief Scientific Officer Criteo BIT.BIO Seattle Children’s - ‘ &. Kathy Wilkinson Kev

  29. Slide 29: It's about time

    It's about time The most committed and passionate geeks driving next gen oncology cell therapeutics eseventybio”

  30. Slide 30: thank you

    —7 thank you eseventybio.

2seventy bio — Investor Presentation (January 2022) on 6ix